-
Je něco špatně v tomto záznamu ?
Hypericin affects cancer side populations via competitive inhibition of BCRP
J. Vargová, J. Mikeš, R. Jendželovský, L. Mikešová, B. Kuchárová, Ľ. Čulka, R. Fedr, J. Remšík, K. Souček, A. Kozubík, P. Fedoročko,
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- ABC transportér z rodiny G, člen 2 metabolismus MeSH
- aldehyddehydrogenasa metabolismus MeSH
- analýza přežití MeSH
- buněčné klony MeSH
- buněčné sféroidy účinky léků metabolismus patologie MeSH
- fenotyp MeSH
- karcinogeneze účinky léků metabolismus patologie MeSH
- lidé MeSH
- myši SCID MeSH
- nádorové biomarkery metabolismus MeSH
- nádorové buněčné linie MeSH
- nádorové kmenové buňky účinky léků metabolismus patologie MeSH
- nádorové proteiny metabolismus MeSH
- nádory metabolismus patologie MeSH
- P-glykoprotein metabolismus MeSH
- perylen analogy a deriváty farmakologie MeSH
- substrátová specifita účinky léků MeSH
- vedlejší populace buněk účinky léků patologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: Cancer stem-like cells (CSLCs) are considered a root of tumorigenicity and resistance. However, their identification remains challenging. The use of the side population (SP) assay as a credible marker of CSLCs remains controversial. The SP assay relies on the elevated activity of ABC transporters that, in turn, can be modulated by hypericin (HYP), a photosensitizer and bioactive compound of St. John's Wort (Hypericum perforatum), a popular over-the-counter antidepressant. Here we aimed to comprehensively characterize the SP phenotype of cancer cells and to determine the impact of HYP on these cells. METHODS: Flow cytometry and sorting-based assays were employed, including CD24-, CD44-, CD133-, and ALDH-positivity, clonogenicity, 3D-forming ability, ABC transporter expression and activity, and intracellular accumulation of HYP/Hoechst 33342. The tumorigenic ability of SP, nonSP, and HYP-treated cells was verified by xenotransplantation into immunodeficient mice. RESULTS: The SP phenotype was associated with elevated expression of several investigated transporters and more intensive growth in non-adherent conditions but not with higher clonogenicity, tumorigenicity or ALDH-positivity. Despite stimulated BCRP level and MRP1 activity, HYP reversibly decreased the SP proportion, presumably via competitive inhibition of BCRP. HYP-selected SP cells acquired additional traits of resistance and extensively eliminated HYP. CONCLUSIONS: Our results suggest that SP is not an unequivocal CSLC-marker. However, SP could play an important role in modulating HYP-treatment and serve as a negative predictive tool for HYP-based therapies. Moreover, the use of supplements containing HYP by cancer patients should be carefully considered, due to its proposed effect on drug efflux and complex impact on tumor cells, which have not yet been sufficiently characterized.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033150
- 003
- CZ-PrNML
- 005
- 20181009110809.0
- 007
- ta
- 008
- 181008s2018 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2018.01.074 $2 doi
- 035 __
- $a (PubMed)29665654
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Vargová, Jana $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
- 245 10
- $a Hypericin affects cancer side populations via competitive inhibition of BCRP / $c J. Vargová, J. Mikeš, R. Jendželovský, L. Mikešová, B. Kuchárová, Ľ. Čulka, R. Fedr, J. Remšík, K. Souček, A. Kozubík, P. Fedoročko,
- 520 9_
- $a OBJECTIVE: Cancer stem-like cells (CSLCs) are considered a root of tumorigenicity and resistance. However, their identification remains challenging. The use of the side population (SP) assay as a credible marker of CSLCs remains controversial. The SP assay relies on the elevated activity of ABC transporters that, in turn, can be modulated by hypericin (HYP), a photosensitizer and bioactive compound of St. John's Wort (Hypericum perforatum), a popular over-the-counter antidepressant. Here we aimed to comprehensively characterize the SP phenotype of cancer cells and to determine the impact of HYP on these cells. METHODS: Flow cytometry and sorting-based assays were employed, including CD24-, CD44-, CD133-, and ALDH-positivity, clonogenicity, 3D-forming ability, ABC transporter expression and activity, and intracellular accumulation of HYP/Hoechst 33342. The tumorigenic ability of SP, nonSP, and HYP-treated cells was verified by xenotransplantation into immunodeficient mice. RESULTS: The SP phenotype was associated with elevated expression of several investigated transporters and more intensive growth in non-adherent conditions but not with higher clonogenicity, tumorigenicity or ALDH-positivity. Despite stimulated BCRP level and MRP1 activity, HYP reversibly decreased the SP proportion, presumably via competitive inhibition of BCRP. HYP-selected SP cells acquired additional traits of resistance and extensively eliminated HYP. CONCLUSIONS: Our results suggest that SP is not an unequivocal CSLC-marker. However, SP could play an important role in modulating HYP-treatment and serve as a negative predictive tool for HYP-based therapies. Moreover, the use of supplements containing HYP by cancer patients should be carefully considered, due to its proposed effect on drug efflux and complex impact on tumor cells, which have not yet been sufficiently characterized.
- 650 _2
- $a ABC transportér z rodiny G, člen 2 $x metabolismus $7 D000070997
- 650 _2
- $a P-glykoprotein $x metabolismus $7 D020168
- 650 _2
- $a aldehyddehydrogenasa $x metabolismus $7 D000444
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a karcinogeneze $x účinky léků $x metabolismus $x patologie $7 D063646
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a buněčné klony $7 D002999
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a myši SCID $7 D016513
- 650 _2
- $a nádorové proteiny $x metabolismus $7 D009363
- 650 _2
- $a nádory $x metabolismus $x patologie $7 D009369
- 650 _2
- $a nádorové kmenové buňky $x účinky léků $x metabolismus $x patologie $7 D014411
- 650 _2
- $a perylen $x analogy a deriváty $x farmakologie $7 D010569
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a vedlejší populace buněk $x účinky léků $x patologie $7 D058985
- 650 _2
- $a buněčné sféroidy $x účinky léků $x metabolismus $x patologie $7 D018874
- 650 _2
- $a substrátová specifita $x účinky léků $7 D013379
- 650 _2
- $a analýza přežití $7 D016019
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mikeš, Jaromír $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
- 700 1_
- $a Jendželovský, Rastislav $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
- 700 1_
- $a Mikešová, Lucia $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
- 700 1_
- $a Kuchárová, Barbora $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
- 700 1_
- $a Čulka, Ľubomír $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
- 700 1_
- $a Fedr, Radek $u Institute of Biophysics of the Czech Academy of Sciences, Brno, Královopolská 135, 612 65, Brno, Czech Republic; Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91, Brno, Czech Republic.
- 700 1_
- $a Remšík, Ján $u Institute of Biophysics of the Czech Academy of Sciences, Brno, Královopolská 135, 612 65, Brno, Czech Republic; Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic.
- 700 1_
- $a Souček, Karel $u Institute of Biophysics of the Czech Academy of Sciences, Brno, Královopolská 135, 612 65, Brno, Czech Republic; Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic.
- 700 1_
- $a Kozubík, Alois $u Institute of Biophysics of the Czech Academy of Sciences, Brno, Královopolská 135, 612 65, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic.
- 700 1_
- $a Fedoročko, Peter $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic. Electronic address: peter.fedorocko@upjs.sk.
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 99, č. - (2018), s. 511-522
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29665654 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181009111257 $b ABA008
- 999 __
- $a ok $b bmc $g 1340029 $s 1030144
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 99 $c - $d 511-522 $e 20180220 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20181008